"Pyrazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
| Descriptor ID |
D011720
|
| MeSH Number(s) |
D03.383.129.539
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrazoles".
Below are MeSH descriptors whose meaning is more specific than "Pyrazoles".
This graph shows the total number of publications written about "Pyrazoles" by people in this website by year, and whether "Pyrazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2001 | 2 | 0 | 2 |
| 2002 | 0 | 1 | 1 |
| 2003 | 2 | 1 | 3 |
| 2005 | 0 | 1 | 1 |
| 2006 | 3 | 0 | 3 |
| 2007 | 3 | 0 | 3 |
| 2008 | 2 | 0 | 2 |
| 2009 | 0 | 2 | 2 |
| 2010 | 4 | 1 | 5 |
| 2011 | 8 | 2 | 10 |
| 2012 | 3 | 3 | 6 |
| 2013 | 6 | 2 | 8 |
| 2014 | 6 | 4 | 10 |
| 2015 | 5 | 5 | 10 |
| 2016 | 6 | 5 | 11 |
| 2017 | 3 | 4 | 7 |
| 2018 | 4 | 5 | 9 |
| 2019 | 4 | 4 | 8 |
| 2020 | 4 | 4 | 8 |
| 2021 | 3 | 3 | 6 |
| 2022 | 0 | 5 | 5 |
| 2023 | 0 | 4 | 4 |
| 2024 | 1 | 0 | 1 |
| 2025 | 1 | 2 | 3 |
| 2026 | 2 | 3 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrazoles" by people in Profiles.
-
Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial. JAMA Cardiol. 2026 05 01; 11(5):446-454.
-
Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial. J Card Fail. 2026 May; 32(5):864-876.
-
Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial. Blood. 2026 Mar 26; 147(13):1433-1446.
-
Ruxolitinib and heart failure outcomes among patients with myelofibrosis. Leuk Lymphoma. 2026 May; 67(6):1335-1342.
-
Acoramidis in transthyretin amyloid cardiomyopathy: expanding evidence from ATTRibute-CM. Future Cardiol. 2026 02; 22(2):119-133.
-
Cellular hierarchies of embryonal tumors with multilayered rosettes are shaped by oncogenic microRNAs and receptor-ligand interactions. Nat Cancer. 2025 Jun; 6(6):1035-1055.
-
Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review. Target Oncol. 2025 Mar; 20(2):217-234.
-
Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia. Blood. 2025 02 06; 145(6):577-589.
-
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. N Engl J Med. 2024 09 12; 391(10):885-898.
-
Antithrombotic and prohemorrhagic actions of different concentrations of apixaban in patients exposed to single and dual antiplatelet regimens. Sci Rep. 2023 12 27; 13(1):22969.